# Wolfgang Janni

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/wolfgang-janni/

## Facts

| Field | Value |
| --- | --- |
| Citations | 30,556 |
| Field | Breast Cancer Treatment Studies |
| h-index | 70 |
| i10-index | 328 |
| Last Known Institution | Universität Ulm |
| OpenAlex ID | https://openalex.org/A5045891981 |
| ORCID iD | https://orcid.org/0000-0001-5911-2400 |
| Works | 953 |

## Researcher papers

- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/early-breast-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials](https://scholariq.org/papers/clinical-and-molecular-characteristics-of-her2-low-positive-breast-cancer-pooled/)
- [Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer](https://scholariq.org/papers/pooled-analysis-of-the-prognostic-relevance-of-circulating-tumor-cells-in/)
- [Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials](https://scholariq.org/papers/trastuzumab-for-early-stage-her2-positive-breast-cancer-a-meta-analysis-of-13/)
- [Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial](https://scholariq.org/papers/bevacizumab-and-platinum-based-combinations-for-recurrent-ovarian-cancer-a/)
- [13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus - Opinion of a German Team of Experts (Zurich 2013)](https://scholariq.org/papers/13th-st-gallen-international-breast-cancer-conference-2013-primary-therapy-of/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Cells and Metastasis](https://scholariq.org/topics/cancer-cells-and-metastasis/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Universität Ulm](https://scholariq.org/institutions/universitat-ulm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.